Medication info
Yuhan Mmet Tablet 10/1000 mg (Empagliflozin, Metformin)

Yuhan Mmet Tablet 10/1000 mg (Empagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›10mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Yuhan Corporation
Appearance
Yellow oval film-coated extended-release tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501542 · Approved 2025.06.23 · Insurance code 642106330

Summary

Main use
Improvement of blood glucose control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: empagliflozin 25mg and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal in the evening. Take 1 extended-release tablet of this medicine 10/1000 mg or 25/1000 mg once daily. Patients taking this medicine as 5/1000 mg or 12.5/1000 mg extended-release tablets should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the metformin hydrochloride dose should be increased gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended initial dose when taking this medicine is a total daily dose of empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching to this medicine from combination therapy with empagliflozin and metformin should receive their existing doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. When this medicine is coadministered with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. (See Precautions for Use, 4. Adverse Reactions and 6. Interactions.) Because dosage adjustment based on renal function may be necessary, assessment of renal function is recommended before starting this medicine and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used with adjustment of the metformin hydrochloride dose as follows, if it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, discontinue this medicine immediately. In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Yuhan Corporation

Efficacy & effects

Improvement of blood glucose control in adults with type 2 diabetes

  • Type 2 diabetes with difficulty in blood sugar control
  • cardiovascular disease
View approved original text

This medication is used to improve blood sugar control in adults with type 2 diabetes whose condition is not adequately managed by diet and exercise alone, by using empagliflozin and metformin together. Furthermore, care should be taken when administering to patients with concurrent cardiovascular disease to confirm the impact on the occurrence of cardiovascular events. Therefore, this medication helps to manage blood sugar more effectively and reduce the risk of diabetes-related complications.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: empagliflozin 25mg and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal in the evening. Take 1 extended-release tablet of this medicine 10/1000 mg or 25/1000 mg once daily. Patients taking this medicine as 5/1000 mg or 12.5/1000 mg extended-release tablets should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the metformin hydrochloride dose should be increased gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended initial dose when taking this medicine is a total daily dose of empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching to this medicine from combination therapy with empagliflozin and metformin should receive their existing doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. When this medicine is coadministered with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. (See Precautions for Use, 4. Adverse Reactions and 6. Interactions.) Because dosage adjustment based on renal function may be necessary, assessment of renal function is recommended before starting this medicine and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used with adjustment of the metformin hydrochloride dose as follows, if it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, discontinue this medicine immediately. In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Precautions

This medication is used for the treatment of diabetes and helps lower blood sugar. When taking this medication, caution is advised as a rare side effect called severe lactic acidosis may occur. Lactic acidosis can lead to an excessive build-up of lactic acid in the body and can become dangerous, sometimes even life-threatening. Also, when taken with insulin or other sugar-lowering agents, hypoglycemia may occur, so blood sugar levels should be monitored closely. This medication should not be administered to patients with poor kidney function, acute infections, dehydration, or severe heart issues. It is especially prohibited in patients with moderate to severe renal impairment. Before receiving iodinated contrast agents used in radiological examinations, this medication should be discontinued, and it should not be readministered until renal function is confirmed to be normal after the examination. Scheduled surgeries or scenarios such as severe infections or trauma may require a temporary suspension of medication, with resumption after recovery. This medication contains lactose, so patients with hereditary issues like lactose intolerance should not take it. Regular kidney function tests should be conducted during treatment, especially for elderly patients or those at risk of declining kidney function. In situations with a risk of fluid loss, body status should be carefully monitored to prevent dehydration or hypotension. This medication may cause side effects such as genital and urinary tract infections, increased urination, liver function abnormalities, gastrointestinal disturbances (nausea, vomiting, diarrhea, etc.), so any unusual symptoms should be discussed with a physician. Pregnant women or those with the potential to become pregnant, as well as nursing mothers, are advised against taking this medication. Elderly individuals are at risk for decreased kidney function and require dose adjustments and regular testing. In cases of overdose, serious side effects like lactic acidosis may occur, necessitating immediate hospital treatment, and blood dialysis may be required. This medication should be swallowed whole without crushing or chewing, and the tablet coating may be excreted but this is normal. Alcohol consumption during treatment should be avoided, and potential drug interactions with other medications should be discussed with a physician or pharmacist. While taking this medication, patients should pay close attention to symptoms of hypoglycemia or infection, and notify healthcare providers immediately if adverse symptoms occur.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased vitamin B12 and deficiency
  • ketoacidosis
  • lactic acidosis
  • nausea
  • vomiting
  • diarrhea
Show 157 more
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • altered taste sensation
  • pruritus
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased blood creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • perineal necrosis
  • vulvovaginitis
  • balanitis
  • decreased fluid volume
  • increased blood creatinine
  • decreased glomerular filtration rate
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • pancreatic carcinoma
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • colonic hemorrhage
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • acute pyelonephritis
  • sepsis
  • subcutaneous abscess
  • adnexal-ovarian abscess
  • vestibular neuritis
  • headache
  • positional dizziness
  • asthenia
  • chest discomfort
  • chest pain
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • weight loss
  • urolithiasis
  • vulvar pruritus
  • benign prostatic hyperplasia
  • diabetic retinopathy
  • diplopia
  • hypertension
  • insomnia
  • anxiety
  • depression
  • sleep disturbances
  • otalgia
  • positional vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • dermal cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal abrasion
  • glaucoma
  • macular fibrosis
  • eye discomfort
  • conjunctival hyperemia
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • serous retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • nasal bleeding
  • asthma
  • senile dyspnea
  • wet cough
  • allergic rhinitis
  • residual sputum
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • fall
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral artery obstructive disease
  • benign neoplasm of the Vater ampulla
  • benign ovarian tumor
  • bladder cancer
  • cholesteatoma
  • gastric cancer
  • leiomyoma
  • pancreatic carcinoma
  • rectal cancer
  • thyroid cancer
  • uterine leiomyoma
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is best to maintain a storage temperature between 1 and 30 degrees Celsius. Proper storage will help to maintain the medication's efficacy for a longer duration.

Appearance and packaging

Appearance

Yellow oval film-coated extended-release tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.